ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0282

Predicting the Optimal Approach to IV Iron: Understanding the Requirements to Attain and Maintain Target Haemoglobin in Non-Haemodialysis CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Brown, Christopher, Swansea Bay University Health Board, Port Talbot, Neath Port Talbot, United Kingdom
  • Mikhail, Ashraf I., Swansea Bay University Health Board, Port Talbot, Neath Port Talbot, United Kingdom
  • Cameron, Felicity Paige, Swansea Bay University Health Board, Port Talbot, Neath Port Talbot, United Kingdom
  • Greene, Giles, Cardiff University, Cardiff, South Glamorgan, United Kingdom

The UK Renal Association recommends a High-dose Low-frequency (HDLF) approach to IV iron management for non-haemodialysis (non-HD) CKD. HDLF is defined as at least 500mg per infusion with a maximum of two infusions. Reducing the frequency of repeat infusion benefits healthcare resource & patient acceptance. This study retrospectively examined IV iron strategies used to attain & maintain effective treatment response.These data may predict a future dosing strategy that is more likely to meet iron requirements in a single, or at least a minimum number of infusions.


This retrospective analysis of 170 non-HD patients examined a 12 month Hb response to a single infusion of iron isomaltoside (HDLF1); max permissible 20mg/kg/infusion. The cumulative amount of iron to attain and maintain a target Hb >100g/L was determined.


Of the 170 patients 111 (65%) attained a Hb target of 100g/L with a mean single infusion dose (HDLF1) of 985mg (equating to 11.9mg/kg); the mean time to Hb target was 91 days. Repeat doses were defined as either HDLF (>500mg) or LDHF (Low dose - High frequency). Where a 2nd dose was given the mean dose for the two approaches was 946mg for HDLF and 200mg for LDHF. The number with at least 1 additional infusion given by 3, 6 & 12 months were: for HDLF n=26, 56, & 113, & for LDHF n=24, 43 & 70.


These data suggest that the majority of patients with a Hb <100g/L who are treated with a 12mg/kg HDLF approach to IV iron will require repeated infusions within 12 months. The maximum permissible dose in a single infusion varies by product label. In this UK study the maximum single infusion dose of 20mg/kg meant that the mean cumulative iron requirements at 3 & 6 months could have been achieved in one infusion. At 12 months this threshold was exceeded. This gives an insight into how future approaches to iron dosing could be considered.


  • Commercial Support